Contracting practices and lack of competition among large healthcare group purchasing organizations and drug wholesalers – and their impact on the generic pharmaceutical market – are among topics in request for public comments by the agency.

Contracting practices and lack of competition among large healthcare group purchasing organizations and drug wholesalers – and their impact on the generic pharmaceutical market – are among topics in request for public comments by the agency.

The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.

More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.